MNMD
Mind Medicine (MindMed) Inc.
1W: +1.8%
1M: +6.5%
3M: +51.6%
YTD: +34.8%
1Y: +174.5%
3Y: +534.1%
5Y: -57.7%
$18.39
-0.27 (-1.45%)
After Hours: $18.54 (+0.14, +0.79%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.4B
52W Range4.7-19.62
Volume1,378,818
Avg Volume2,525,520
Beta2.62
Dividend—
Analyst Ratings
Company Info
CEORobert Barrow
Employees74
SectorHealthcare
IndustryBiotechnology
IPO Date2016-11-15
Websitemindmed.co
1055 West Hastings Street
Vancouver, BC V6E 2E9
CA
Vancouver, BC V6E 2E9
CA
650 208 2454
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sullivan Mark | S-Sale | 11,278 | $9.77 | 2025-09-25 |
| Barrow Robert | S-Sale | 25,797 | $9.77 | 2025-09-25 |
| Karlin Daniel | S-Sale | 7,704 | $9.77 | 2025-09-25 |
| Sullivan Mark | S-Sale | 11,491 | $6.80 | 2025-06-25 |
| Karlin Daniel | S-Sale | 7,848 | $6.80 | 2025-06-25 |